Sam S. Chang, MD, MBA

In this companion article, Sam S. Chang, MD, MBA, offers his expert perspective on the use of mitomycin gel as a kidney-sparing approach to the management of low-grade upper tract urothelial carcinoma.

In the third interview of the series, Sam S. Chang, MD, MBA, from the Vanderbilt University Medical Center shares key insights into the role of mitomycin gel as a kidney-sparing approach to the treatment of low-grade upper tract urothelial carcinoma.

The role of adjuvant therapy in nonmetastatic muscle invasive bladder cancer, and an overview of promising novel therapies in the treatment pipeline.

An overview of treatment guidelines available to support urologists and medical oncologists who manage patients with bladder cancer.

Administration of systemic therapy and management of side effects in patients with bladder cancer.

The types of healthcare professionals who may play a role in evaluating and diagnosing bladder cancer.